Supplementary Table 2.
Factors associated with bleeding events on treatment or within 48 hours of stopping rivaroxaban (significant p-values are emboldened)
| Bleed (n=10) | No bleed (n=469) | p | |
| Female sex – n (%) | 6 (60) | 287 (61.2) | 1.000 |
| Age – years median(IQR) | 75 (15) | 69 (14) | 0.123 |
| Elective – n (%) | 10 (100) | 436 (93) | 1.000 |
| Hip arthroplasty* – n (%) | 3 (30) | 257 (54.8) | 0.198 |
| Duration of stay – days median (IQR) | 5 (2) | 5 (3) | 0.384 |
| Medical history | |||
| Hypertension – n (%) | 4 (40) | 218 (46.5) | 0.758 |
| Diabetes – n (%) | 0 (0) | 50 (10.7) | 0.609 |
| IHD – n (%) | 2 (20) | 23 (4.9) | 0.091 |
| COPD – n (%) | 1 (10) | 14 (3.0) | 0.275 |
| AF – n (%) | 0 (0) | 11 (2.3) | 1.000 |
| Previous VTE – n (%) | 1 (10) | 7 (1.5) | 0.156 |
| CKD – n (%) | 0 (0) | 3 (0.6) | 1.000 |
| CCF – n (%) | 0 (0) | 1 (0.2) | 1.000 |
| Drug history | |||
| ACEI/ARB – n (%) | 3 (30) | 146 (31.1) | 1.000 |
| Statin – n (%) | 4 (40) | 137 (29.2) | 0.490 |
| Gastric protection – n (%) | 3 (30) | 123 (26.3) | 0.727 |
| CCB – n (%) | 1 (10) | 99 (21.1) | 0.696 |
| Aspirin – n (%) | 2 (20) | 46 (9.8) | 0.264 |
| Thiazide – n (%) | 2 (20) | 39 (8.3) | 0.208 |
| Clopidogrel – n (%) | 0 (0) | 6 (1.3) | 1.000 |
| Anti-retroviral – n (%) | 1 (10) | 5 (1.1) | 0.119 |
| Anticoagulation – n (%) | 0 (0) | 0 (0) | n/a |
| Blood results upon hospital discharge | |||
| Haemoglobin – g/l, median (IQR) | 101.5 (50.55) | 104 (19) | 0.904 |
| Platelets – ×109/l, median (IQR) | 245 (120.75) | 231 (104.5) | 0.668 |
| PT – s, median (IQR) | 10.7 (0.6) | 10.4 (0.7) | 0.275 |
| APTT –s, median (IQR) | 23.9 (3.2) | 25.2 (3.2) | 0.028 |
| Urea – mmol/l, median (IQR) | 6.15 (4.33) | 4.6 (2.4) | 0.094 |
| Creatinine – μmol/l, median (IQR) | 83.5 (38.5) | 68 (20) | 0.075 |
| eGFR – ml/min/1.73 m2, median (IQR) | 75.5 (32.75) | 84 (21) | 0.064 |
| Bilirubin – μmol/l, median (IQR) | 10 (7) | 11 (7) | 0.999 |
| ALT – iU/l, median (IQR) | 24 (21.25) | 20 (15) | 0.584 |
| Inpatient thromboprophylaxis | |||
| AES <12 hours, – n (%) | 1 (10) | 31 (6.6) | 0.503 |
| AES 12–24 hours, – n (%) | 3 (30) | 189 (40.3) | 0.747 |
| AES >24 hours – n (%) | 1 (10) | 48 (10.4) | 1.000 |
| AES not administered – n (%) | 5 (50) | 201 (42.9) | 0.751 |
| Enoxaparin <12 hours – n (%) | 9 (90) | 392 (83.6) | 1.000 |
| Enoxaparin 12–24 hours – n (%) | 1 (10) | 30 (6.4) | 0.491 |
| Enoxaparin >24 hours – n (%) | 0 (0) | 46 (9.8) | 0.609 |
| Enoxaparin not administered – n (%) | 0 (0) | 1 (0.2) | 1.000 |
| Enoxaparin duration – days median (IQR) | 5 (1) | 4 (3) | 0.575 |
| Outpatient thromboprophylaxis | |||
| Rivaroxaban start dayo – days median (IQR) | 6 (1) | 6 (4) | 0.653 |
| Rivaroxaban duration (hip) – days median (IQR) | 30*** | 31 (3) | 0.510 |
| Rivaroxaban duration (knee) – days median (IQR) | 9 (2) | 10 (3) | 0.278 |
| Total anticoagulation | |||
| Total anticoagulation (hip) – days median (IQR) | 35*** | 35 (1) | 0.653 |
| Total anticoagulation (knee) – days median (IQR) | 14 (2) | 14 (1) | 0.110 |
*Composite of primary and revision hip arthroplasties. **n=1 patient so the value is absolute rather than median, no IQR. ***n=3 patients so the IQR was not available. oNumber of days after surgery that rivaroxaban was commenced.
IHD = ischaemic heart disease; COPD = chronic obstructive pulmonary disease; AF = atrial fibrillation; VTE = venous thromboembolism; CKD = chronic kidney disease; CCF = congestive cardiac failure; ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCB = calcium channel blocker; PT = prothrombin time; APTT = activated partial thromboplastin time; eGFR = estimated glomerular filtration rate; ALT = alanine aminotransferase; AES = anti-embolism stocking; IQR = interquartile range